# Lexeo Therapeutics, Inc.: financial statements, quarterly

LXEO · Nasdaq · CIK 1907108 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lxeo.md) · [Financials](/companies/lxeo/financials.md) · [Filings](/companies/lxeo/filings.md) · [Insiders](/companies/lxeo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lxeo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [17.2](/filings/0000950170-24-125943.md) | [8.2 d](/filings/0000950170-25-043486.md) | [15.7](/filings/0000950170-25-068536.md) | [16.6](/filings/0000950170-25-108427.md) | [23.4](/filings/0001193125-25-265757.md) | [18.4 d](/filings/0001193125-26-132085.md) | [17.2](/filings/0001193125-26-215678.md) | [14.7](/filings/0001193125-26-345724.md) | [15.7](/filings/0001193125-25-265757.md) | [16.2 d](/filings/0001193125-26-132085.md) | [15.7](/filings/0001193125-26-215678.md) | [19.0](/filings/0001193125-26-345724.md) |
| Operating income | $m | [(20.3)](/filings/0000950170-24-125943.md) | [(15.0) d](/filings/0000950170-25-043486.md) | [(23.3)](/filings/0000950170-25-068536.md) | [(23.6)](/filings/0000950170-25-108427.md) | [(31.5)](/filings/0001193125-25-265757.md) | [(27.4) d](/filings/0001193125-26-132085.md) | [(33.8)](/filings/0001193125-26-215678.md) | [(30.7)](/filings/0001193125-26-345724.md) | [(21.6)](/filings/0001193125-25-265757.md) | [(23.1) d](/filings/0001193125-26-132085.md) | [(22.3)](/filings/0001193125-26-215678.md) | [(28.0)](/filings/0001193125-26-345724.md) |
| Interest expense | $m | [0.1](/filings/0000950170-23-069192.md) | [0.1 d](/filings/0000950170-24-028941.md) | [0.0](/filings/0000950170-24-056247.md) | [0.0](/filings/0000950170-24-095057.md) | [0.0](/filings/0001193125-25-265757.md) | [0.0 d](/filings/0001193125-26-132085.md) | [0.0](/filings/0001193125-26-215678.md) | [0.0](/filings/0001193125-26-345724.md) | [0.0](/filings/0001193125-25-265757.md) | [0.0 d](/filings/0001193125-26-132085.md) | [0.0](/filings/0001193125-26-215678.md) | [0.0](/filings/0001193125-26-345724.md) |
| Net income | $m | [(20.1)](/filings/0000950170-24-125943.md) | [(14.2) d](/filings/0000950170-25-043486.md) | [(21.7)](/filings/0001193125-25-265757.md) | [(21.2)](/filings/0001193125-25-265757.md) | [(29.5)](/filings/0001193125-25-265757.md) | [(25.9) d](/filings/0001193125-26-132085.md) | [(32.7)](/filings/0001193125-26-345724.md) | [(26.1)](/filings/0001193125-26-345724.md) | [(20.3)](/filings/0001193125-25-265757.md) | [(21.0) d](/filings/0001193125-26-345724.md) | [(20.2)](/filings/0001193125-26-345724.md) | [(25.9)](/filings/0001193125-26-345724.md) |
| Diluted EPS | $ per share | [(12.36)](/filings/0000950170-24-125943.md) | not reported | [(0.77)](/filings/0000950170-25-068536.md) | [(0.64)](/filings/0000950170-25-108427.md) | [(0.89)](/filings/0001193125-25-265757.md) | not reported | [(0.99)](/filings/0001193125-26-215678.md) | [(0.60)](/filings/0001193125-26-345724.md) | [(0.33)](/filings/0001193125-25-265757.md) | not reported | [(0.25)](/filings/0001193125-26-215678.md) | [(0.30)](/filings/0001193125-26-345724.md) |
| Basic EPS | $ per share | [(12.36)](/filings/0000950170-24-125943.md) | not reported | [(0.77)](/filings/0000950170-25-068536.md) | [(0.64)](/filings/0000950170-25-108427.md) | [(0.89)](/filings/0001193125-25-265757.md) | not reported | [(0.99)](/filings/0001193125-26-215678.md) | [(0.60)](/filings/0001193125-26-345724.md) | [(0.33)](/filings/0001193125-25-265757.md) | not reported | [(0.25)](/filings/0001193125-26-215678.md) | [(0.30)](/filings/0001193125-26-345724.md) |

- Revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [35.4](/filings/0000950170-23-069192.md) | [121](/filings/0000950170-25-043486.md) | [195](/filings/0000950170-24-056247.md) | [175](/filings/0000950170-24-095057.md) | [157](/filings/0000950170-24-125943.md) | [35.0](/filings/0001193125-26-132085.md) | [28.9](/filings/0000950170-25-068536.md) | [35.5](/filings/0000950170-25-108427.md) | [41.0](/filings/0001193125-25-265757.md) | [63.0](/filings/0001193125-26-345724.md) | [71.8](/filings/0001193125-26-215678.md) | [92.8](/filings/0001193125-26-345724.md) |
| Current assets | $m | [38.9](/filings/0000950170-23-069192.md) | [124](/filings/0000950170-25-043486.md) | [198](/filings/0000950170-24-056247.md) | [177](/filings/0000950170-24-095057.md) | [159](/filings/0000950170-24-125943.md) | [126](/filings/0001193125-26-132085.md) | [105](/filings/0000950170-25-068536.md) | [140](/filings/0000950170-25-108427.md) | [128](/filings/0001193125-25-265757.md) | [188](/filings/0001193125-26-345724.md) | [201](/filings/0001193125-26-215678.md) | [218](/filings/0001193125-26-345724.md) |
| Total assets | $m | [54.7](/filings/0000950170-23-069192.md) | [140](/filings/0000950170-25-043486.md) | [213](/filings/0000950170-24-056247.md) | [192](/filings/0000950170-24-095057.md) | [174](/filings/0000950170-24-125943.md) | [147](/filings/0001193125-26-132085.md) | [126](/filings/0000950170-25-068536.md) | [176](/filings/0000950170-25-108427.md) | [144](/filings/0001193125-25-265757.md) | [269](/filings/0001193125-26-345724.md) | [250](/filings/0001193125-26-215678.md) | [255](/filings/0001193125-26-345724.md) |
| Current liabilities | $m | [23.0](/filings/0000950170-23-069192.md) | [17.2](/filings/0000950170-25-043486.md) | [21.6](/filings/0000950170-24-056247.md) | [18.9](/filings/0000950170-24-095057.md) | [26.8](/filings/0000950170-24-125943.md) | [22.8](/filings/0001193125-26-132085.md) | [30.8](/filings/0000950170-25-068536.md) | [31.6](/filings/0000950170-25-108427.md) | [17.3](/filings/0001193125-25-265757.md) | [16.8](/filings/0001193125-26-345724.md) | [14.2](/filings/0001193125-26-215678.md) | [15.7](/filings/0001193125-26-345724.md) |
| Total liabilities | $m | [32.5](/filings/0000950170-23-069192.md) | [26.3](/filings/0000950170-25-043486.md) | [30.3](/filings/0000950170-24-056247.md) | [27.1](/filings/0000950170-24-095057.md) | [34.5](/filings/0000950170-24-125943.md) | [30.1](/filings/0001193125-26-132085.md) | [37.6](/filings/0000950170-25-068536.md) | [37.9](/filings/0000950170-25-108427.md) | [23.0](/filings/0001193125-25-265757.md) | [22.0](/filings/0001193125-26-345724.md) | [18.9](/filings/0001193125-26-215678.md) | [19.8](/filings/0001193125-26-345724.md) |
| Shareholders' equity | $m | [(163)](/filings/0000950170-24-125943.md) | [114](/filings/0001193125-26-132085.md) | [183](/filings/0001193125-25-265757.md) | [165](/filings/0001193125-25-265757.md) | [139](/filings/0001193125-25-265757.md) | [117](/filings/0001193125-26-345724.md) | [88.1](/filings/0001193125-26-345724.md) | [138](/filings/0001193125-26-345724.md) | [121](/filings/0001193125-25-265757.md) | [247](/filings/0001193125-26-345724.md) | [231](/filings/0001193125-26-345724.md) | [235](/filings/0001193125-26-345724.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(13.9) d](/filings/0000950170-24-125943.md) | [(14.0) d](/filings/0000950170-25-043486.md) | [(14.9)](/filings/0000950170-25-068536.md) | [(20.2) d](/filings/0000950170-25-108427.md) | [(17.8) d](/filings/0001193125-25-265757.md) | [(28.3) d](/filings/0001193125-26-132085.md) | [(21.7)](/filings/0001193125-26-215678.md) | [(27.2) d](/filings/0001193125-26-345724.md) | [(29.5) d](/filings/0001193125-25-265757.md) | [(20.1) d](/filings/0001193125-26-132085.md) | [(21.1)](/filings/0001193125-26-215678.md) | [(17.6) d](/filings/0001193125-26-345724.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-125943.md) | [0.1 d](/filings/0000950170-25-043486.md) | [0.2](/filings/0000950170-25-068536.md) | [0.2 d](/filings/0000950170-25-108427.md) | [0.1 d](/filings/0001193125-25-265757.md) | [0.0 d](/filings/0001193125-26-132085.md) | not reported | not reported | [0.3 d](/filings/0001193125-25-265757.md) | [0.0 d](/filings/0001193125-26-132085.md) | [0.0](/filings/0001193125-26-215678.md) | [0.0 d](/filings/0001193125-26-345724.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2022-09-30) | period not labelled (2023-03-31) | period not labelled (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [1.6](/filings/0000950170-23-069192.md) | [1.6](/filings/0000950170-24-056247.md) | [1.6](/filings/0000950170-24-095057.md) | [1.6](/filings/0000950170-24-125943.md) | [28.0](/filings/0000950170-25-068536.md) | [33.0](/filings/0000950170-25-108427.md) | [33.1](/filings/0001193125-25-265757.md) | [33.1](/filings/0001193125-26-215678.md) | [43.6](/filings/0001193125-26-345724.md) | [61.0](/filings/0001193125-25-265757.md) | [81.2](/filings/0001193125-26-215678.md) | [85.6](/filings/0001193125-26-345724.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 82,046,255 at 2026-08-10, from the cover of the [10-Q filed 2026-08-12](/filings/0001193125-26-345724.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. No prices; not investment advice.